UGT1A1 and Hyperbilirubinemia: For carriers of UGT1A1*28/*28, *28/*37, *37/*37, and −364 TT, the CPIC guidelines recommend counseling on the possibility of developing hyperbilirubinemia before the initiation of the therapy [99].